With respect to CXCR4-targeted therapies in glioblastoma, the first and most studied CXCR4 antagonist, AMD3100 (Plerixafor), has been reported to inhibit the growth of GBM36 and to reduce glioblastoma stem cell survival in preclinical studies [39]. The gene discussed is CXCR4; the disease is glioblastoma.